Pretreatment with [131I] metaiodobenzylguanidine and surgical resection of advanced neuroblastoma
Pretreatment with [131I] metaiodobenzylguanidine and surgical resection of advanced neuroblastoma
复制标题
DOI：
10.1055/s-2008-1066495
复制
发表时间：
1996-06-01
影响因子：
1.8
通讯作者：
Voute, PA
中科院分区：
文献类型：
--
作者：
vanHasselt, EJ;Heij, HA;Voute, PA
131 I-间碘苄胍预处理后手术切除治疗晚期神经母细胞瘤（3期和4期）已经研究了两个档位后的可切除性、发病率和死亡率、存活率，控制远处转移和血清LDH水平作为预后因素。1例晚期神经母细胞瘤先行MIBG放疗后行手术切除，16例为4期。MIBG治疗2 ~ 6个疗程，17例获得大体完全切除。两名患者发生了与手术直接相关的并发症，一名患者因此死亡。MIBG治疗部分缓解13例，稳定8例，部分缓解组2年生存率86%，稳定组2年生存率28%。由于患者的一般情况良好，MIBG预处理和手术之间的间隔可以很短，随访至1994年12月，13名儿童存活3至47个月。术前MIBG治疗晚期神经母细胞瘤与诱导化疗疗效相当，但毒性较低。
Pretreatment with [131I] metaiodobenzylguanidine (MIBG) followed by surgical resection in advanced neuroblastoma (stage 3 and 4) has been studied in relation to resectability morbidity and mortality survival rate after two gears, control of distant metastasis and serum levels of LDH as prognostic factors.Twenty-one patients with advanced neuroblastoma were primarily treated with MIBG radiotherapy followed by surgical resection.Sixteen patients had stage 4 disease. Between 2 and 6 courses of MIBG treatment were given per patient.In 17 patients gross complete resection was achieved. Two patients developed complications directly related to the operation, one died as a result of this. The overall mortality was 38%.MIBG therapy resulted in partial response in 13 patients and in stable disease in 8 patients.Two years survival in the group with partial response was 86% and in the group with stable disease 28%. Because of the resulting excellent general condition of the patients the interval between pretreatment with MIBG and surgery could be very short.Follow-up till December 1994 showed that 13 children were alive for 3 to 47 months. Seven had no evidence of disease.Preoperative MIBG de novo treatment in advanced neuroblastoma is equal to induction chemotherapy but less toxic.